MedTrace Logo

Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.

NCT04199260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2021-08-09

No results posted yet for this study

Summary

Observational clinical study, national, multicentric, prospective, non-comparative, with medical device, under application consistent with CE marking, for the evaluation of Papilocare® effectivness in the normalization of cervix cytological abnormalities caused by HPV.

Conditions

Interventions

DEVICE

papilocare vaginal gel

Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

Sponsors & Collaborators

  • Adknoma Health Research

    collaborator INDUSTRY

  • Procare Health Iberia S.L.

    lead INDUSTRY

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-20
Primary Completion
2021-02-18
Completion
2021-02-18

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04199260 on ClinicalTrials.gov